Akcea Therapeutics Inc logo

AKCA - Akcea Therapeutics Inc Share Price

$17.05 -0.7  -4.1%

Last Trade - 17/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £1.28bn
Enterprise Value £1.08bn
Revenue £169.2m
Position in Universe 2060th / 6416
Bullish
Bearish
Unlock AKCA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AKCA Revenue Unlock AKCA Revenue

Net Income

AKCA Net Income Unlock AKCA Revenue

Normalised EPS

AKCA Normalised EPS Unlock AKCA Revenue

PE Ratio Range

AKCA PE Ratio Range Unlock AKCA Revenue

Dividend Yield Range

AKCA Dividend Yield Range Unlock AKCA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AKCA EPS Forecasts Unlock AKCA Revenue
Profile Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated December 22, 2014
Public Since July 14, 2017
No. of Shareholders: 8
No. of Employees: 248
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 93,901,338
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AKCA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AKCA
Upcoming Events for AKCA
Similar to AKCA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.